Biogen Avonex May 17 approval allowed under orphan regs based on lack of injection-site necrosis, FDA says.
BIOGEN AVONEX APPROVAL ALLOWED BY LACK OF INJECTION-SITE NECROSIS seen with Berlex/Chiron's Betaseron (interferon beta-1b), FDA said in approving the Biogen multiple sclerosis product. In a May 18 "Talk Paper," FDA said that "this new product has been allowed to enter the market because it differs from interferon beta-1b based on an absence of reports of injection site necrosis." FDA does not indicate whether the molecular difference of one amino acid between the products played a role in its decision to allow Avonex on the market despite Chiron's orphan exclusivity for Betaseron.
You may also be interested in...
FDA's licensure of Serono's Rebif marks the first time the agency has overridden orphan drug exclusivity based on an efficacy endpoint, a March 7 1Office of Orphan Products Development memo outlining FDA's rationale for the approval states
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011